Loading clinical trials...
Loading clinical trials...
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Three Different Doses of BMS-582949 Given Orally to Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this clinical research study is to learn if BMS-582949 alone is an effective treatment for moderate to severe psoriasis. The safety of the drug and the effectiveness of each dose will also be studied.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Local Institution
Kogarah, New South Wales, Australia
Local Institution
Greenslopes, Queensland, Australia
Local Institution
North Adelaide, South Australia, Australia
Local Institution
Carlton, Victoria, Australia
Local Institution
Malvern, Victoria, Australia
Local Institution
Calgary, Alberta, Canada
Local Institution
Edmonton, Alberta, Canada
Local Institution
Surrey, British Columbia, Canada
Local Institution
Winnipeg, Manitoba, Canada
Local Institution
St. John's, Newfoundland and Labrador, Canada
Start Date
August 1, 2007
Primary Completion Date
January 1, 2009
Completion Date
April 1, 2009
Last Updated
December 7, 2015
99
ACTUAL participants
BMS-582949
DRUG
Placebo
DRUG
Lead Sponsor
Bristol-Myers Squibb
NCT07449234
NCT07116967
NCT07250802
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions